Literature DB >> 33570661

GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.

Zheng Hua Piao1, Xin Cheng Zhou2, Jia Yi Chen2.   

Abstract

Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid carcinoma (LSC) and organizing pleuritis (OP). Because SMM often does not express mesothelial markers, it is very difficult to distinguish from LSC and OP. GATA-binding protein 3 (GATA3) is a specific immunohistochemical (IHC) marker of breast and urothelial carcinoma. We routinely find that GATA is expressed in MM; however, GATA3 expression in SMM and its reference value for distinguishing SMM from LSC and OP remain unclear. Here, we used IHC methods to detect the expression of GATA3 and classic mesothelial markers in 17 SMM, 12 LSC, and 7 OP cases. We detected the following expression rates in SMM versus LSC cases: GATA3 (70.6% vs. 16.7%, p = 0.008), calretinin (52.9% vs. 8.3%, p = 0.019), Wilms tumor (WT)-1 (64.7% vs. 0%, p = 0.000), D2-40 (47.1% vs. 16.7%, p = 0.126), CK5/6 (35.3% vs. 25.0%, p = 0.694), and pan-cytokeratin (CKpan) (88.2% vs. 100.0%, p = 0.498). The specificities of calretinin, WT-1, and GATA3 in distinguishing SMM from LSC were 91.7%, 100%, and 83.3%, respectively, and combinations of any two of these three markers exhibited 100% specificity for SMM. Notably, the sensitivity of calretinin+/WT1+ staining for SMM was only 23.5%, which increased to 64.7% after including GATA3. Furthermore, all OP cases showed partial or diffuse expression of CKpan, WT-1, and D2-40 but no GATA3 and calretinin expression. In conclusion, GATA3 is an IHC marker with excellent sensitivity and specificity for SMM, and the combined consideration of GATA3, calretinin, and WT-1 was best for distinguishing SMM from LSC. Moreover, CKpan, WT-1, and D2-40 had no value for distinguishing SMM from OP, and GATA3 and calretinin were the most specific markers for distinguishing these two lesions.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  GATA3; Immunohistochemistry; Lung sarcomatoid carcinoma; Organizing pleuritis; Pathologic diagnosis; Sarcomatoid malignant mesothelioma

Year:  2021        PMID: 33570661     DOI: 10.1007/s00428-021-03048-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  13 in total

Review 1.  Spindle cell tumors of the pleura: differential diagnosis.

Authors:  Monica Rdzanek; Raoul Fresco; Harvey I Pass; Michele Carbone
Journal:  Semin Diagn Pathol       Date:  2006-02       Impact factor: 3.464

2.  Improving the Accuracy of Mesothelioma Diagnosis in China.

Authors:  Zhenying Guo; Michele Carbone; Xing Zhang; Dan Su; Wenyong Sun; Jianlin Lou; Zhibin Gao; Dichu Shao; Junqiang Chen; Gu Zhang; Jinlin Hu; Kaiyan Chen; Fang Wang; Harvey I Pass; Herbert Yu; Andrea Napolitano; Haining Yang; Weimin Mao
Journal:  J Thorac Oncol       Date:  2016-12-19       Impact factor: 15.609

3.  The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.

Authors:  Sarita Prabhakaran; Ashleigh Hocking; Chankyung Kim; Matthew Hussey; Sonja Klebe
Journal:  Hum Pathol       Date:  2020-09-02       Impact factor: 3.466

4.  Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.

Authors:  D R Lucas; H I Pass; S K Madan; N V Adsay; A Wali; P Tabaczka; F Lonardo
Journal:  Histopathology       Date:  2003-03       Impact factor: 5.087

5.  Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.

Authors:  Sonja Klebe; Noel A Brownlee; Annabelle Mahar; James L Burchette; Thomas A Sporn; Robin T Vollmer; Victor L Roggli
Journal:  Mod Pathol       Date:  2010-01-15       Impact factor: 7.842

6.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.

Authors:  Albert Y Chu; Leslie A Litzky; Theresa L Pasha; Geza Acs; Paul J Zhang
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

7.  'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  2003-11       Impact factor: 5.087

8.  Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Authors:  Yukio Takeshima; Vishwa J Amatya; Kei Kushitani; Mayumi Kaneko; Kouki Inai
Journal:  Histopathology       Date:  2009-05       Impact factor: 5.087

9.  D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.

Authors:  Marc Hinterberger; Tanja Reineke; Martina Storz; Walter Weder; Peter Vogt; Holger Moch
Journal:  Mod Pathol       Date:  2007-02       Impact factor: 7.842

10.  Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry.

Authors:  Kei Kushitani; Yukio Takeshima; Vishwa Jeet Amatya; Osamu Furonaka; Akio Sakatani; Kouki Inai
Journal:  Pathol Int       Date:  2008-02       Impact factor: 2.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.